EGEN-001 (phIL-12-005/PPC)

GENETIC2 trials

Sponsors

EGEN, Inc.

Conditions

Ovarian Neoplasms

Phase 1

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

TerminatedNCT00137865

EGEN, Inc.Ovarian Neoplasms

Start: 2005-08-31End: 2006-10-31Updated: 2013-02-28

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

CompletedNCT00473954

EGEN, Inc.Ovarian Neoplasms

Start: 2007-04-30End: 2009-11-30Updated: 2013-03-26